<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Previous studies have shown that patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e>, including those with diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, are more likely to die of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> than reach <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This analysis was conducted to determine whether <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> is a more common outcome than cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> in patients with type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, significant <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, and decreased kidney function who were selected for participation in a clinical trial </plain></SENT>
<SENT sid="2" pm="."><plain>STUDY DESIGN: Retrospective analysis of the DIAMETRIC (<z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo> Treatment for <z:hpo ids='HP_0000083'>Renal Insufficiency</z:hpo> Consortium) database derived from 2 prospective randomized controlled clinical trials (IDNT [<z:chebi fb="0" ids="5959">Irbesartan</z:chebi> Diabetic <z:hpo ids='HP_0000112'>Nephropathy</z:hpo> Trial] and RENAAL [Reduction of Endpoints in <z:mp ids='MP_0002057'>Non-Insulin-dependent Diabetes</z:mp> With the <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> <z:chebi fb="0" ids="6541">Losartan</z:chebi>]) </plain></SENT>
<SENT sid="3" pm="."><plain>SETTING &amp; PARTICIPANTS: 3,228 adult patients with type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> from IDNT and RENAAL were combined to establish the DIAMETRIC database </plain></SENT>
<SENT sid="4" pm="."><plain>This is the largest global source of clinical information for patients with type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> who have decreased kidney function and significant <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>INTERVENTION: Angiotensin receptor blocker versus non-angiotensin receptor blocker therapy to slow the progression of type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (in the prospective trials) </plain></SENT>
<SENT sid="6" pm="."><plain>OUTCOMES &amp; MEASUREMENTS: Incidence rates of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Mean follow-up was 2.8 years; 19.5% of patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, approximately 2.5 times the incidence of cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> and 1.5 times the incidence of <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> was more common than cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> subgroups analyzed with the exception of participants with low levels of <z:mp ids='MP_0002871'>albuminuria</z:mp> (albumin excretion &lt;1.0 g/g) and well-preserved levels of kidney function (estimated glomerular filtration rate &gt;45 mL/min/1.73 m(2)) at baseline </plain></SENT>
<SENT sid="9" pm="."><plain>LIMITATIONS: <z:hpo ids='HP_0000001'>All</z:hpo> participants were included in a prospective clinical trial </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Patients with type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, characterized by decreased kidney function and significant <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, are more likely to reach <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> than die during 3 years' mean follow-up </plain></SENT>
<SENT sid="11" pm="."><plain>Given the rapidly increasing number of cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> worldwide, this has implications for predicting future renal replacement therapy requirements </plain></SENT>
</text></document>